In the last three months, 8 analysts have published ratings on DocGo DCGO, offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.56, a high estimate of $11.00, and a low estimate of $6.50. A decline of 16.87% from the prior average price target is evident in the current average.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of DocGo by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Grossman | Stifel | Lowers | Buy | $6.50 | $8.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $9.00 | $10.00 |
| David Grossman | Stifel | Lowers | Buy | $8.00 | $11.00 |
| David Larsen | BTIG | Lowers | Buy | $11.00 | $13.00 |
| Sarah James | Cantor Fitzgerald | Lowers | Overweight | $11.00 | $13.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $10.00 | $11.00 |
| Ryan MacDonald | Needham | Lowers | Buy | $10.00 | $14.00 |
| David Grossman | Stifel | Lowers | Buy | $11.00 | $12.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DocGo. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of DocGo compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of DocGo's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of DocGo's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on DocGo analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering DocGo: A Closer Look
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
DocGo's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, DocGo showcased positive performance, achieving a revenue growth rate of 83.16% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): DocGo's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): DocGo's ROA stands out, surpassing industry averages. With an impressive ROA of 1.66%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.15, DocGo adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
